Novartis CDK4/6 inhibitor LEE011 receives FDA Breakthrough Therapy designation as first-line treatment for advanced...
Novartis announced today that the US FDA has granted Breakthrough Therapy designation to LEE011 (ribociclib),...
Amgen And Advaxis Enter Global Cancer Immunotherapies Collaboration
Amgen and Advaxis, Inc announced a global agreement for the development and commercialization of Advaxis'...
Pfizer and Western Oncolytics Announce Immuno-Oncology Research Collaboration to Investigate Novel Oncolytic Virus Technology
Companies plan to advance Western Oncolytics’ lead preclinical therapy into human testingPotential combination of WO-12...
Economics Drives Thailand led Laboratory Market in ASEAN
Thailand, 2nd largest economy in South East Asia, promotes foreign investment with new S curve...
Janssen Announces Clinical Collaboration with Bristol-Myers Squibb to Evaluate Immuno-oncology Combination in Lung Cancer
Janssen Biotech, Inc. announced it has entered into a clinical study collaboration agreement with Bristol-Myers...
FDA Approves First And Only Single Monthly Injection For A PCSK9 Inhibitor
Amgen announced that the U.S. FDA has approved the Repatha® (evolocumab) Pushtronex™ system (on-body infusor...
EMA accepts Merck’s MAA for cladribine tablets in multiple sclerosis
Merck, a leading science and technology company announced that the EMA to request the company...
Biogen SB5 accepted for review by European Medicines Agency
The Marketing Authorization Application (MAA) for SB5, an adalimumab biosimilar candidate referencing Humira®1, has been...
Abbott laboratories says U.S. FDA approves tecnis symfony intraocular lenses
Approval includes toric version of symfony iol for people with astigmatism lenses provide high-quality...
Regeneron and Sanofi announce approval of praluent (alirocumab) in Japan
Sanofi and Regeneron Pharmaceuticals, Inc. announced that the Ministry of Health, Labor and Welfare in...
